CSIMarket Company Name, Ticker, Suppliers, else..


Kura Oncology Inc   (NASDAQ: KURA)
Other Ticker:  
 


 

Kura Oncology Inc

KURA's Financial Statements and Analysis



Kura Oncology Inc increased first quarter of 2025 net loss per share of $-0.66 compare to net loss per share of $-0.59 recorded in the same quarter a year ago a decrease compare to $-0.20 realized in previous quarter.


first quarter of 2025
Earnings Per Share Revenues
$ -0.66 $  14 Mill
$-0.07     $+14M    



Kura Oncology Inc 's Revenue rose by 0 % in first quarter of 2025 (Mar 31 2025) year on year, to $14 million and declined by -73.82 % sequentially.


Kura Oncology Inc is

More on KURA's Income Statement



Kura Oncology Inc in the first quarter of 2025 recorded net loss of $-57.429 million, an increase from net loss of $-49.525 million in I. Quarter a year ago.

Sequentially net loss advanced

More on KURA's Growth

Kura Oncology Inc Inventories
In Mar 31 2025 company's net cash and cash equivalents decreased by $-173 million, capital expenditures fell by -0.084247.62%, to $0 millions compare to same quarter a year ago

More on KURA's Cash flow Statement


Kura Oncology Inc does not pay out common stock dividend.

In trailing twelve-month period Kura Oncology Inc earned $ 1.27 cash per share, on a free-cash flow basis .

Book value fell by -13.20 % sequentially to $4.17 per share, -30.50% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.17 per share from $ 4.80.

Company issued 1.28 million shares or 1.49 % in Mar 31 2025.


• More on KURA's Dividends

 Market Capitalization (Millions) 526
 Shares Outstanding (Millions) 87
 Total Debt (Millions $) 10
 Revenue (TTM) (Millions $) 68
 Net Income (TTM) (Millions $) -182
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 89




Kura Oncology Inc does not pay out common stock dividend.

In trailing twelve-month period Kura Oncology Inc had $ 1.27 cash flow per share, on a free-cash flow basis .

Book value fell by -13.20 % sequentially to $4.17 per share, -30.50% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.17 per share from $ 4.80.

Company issued 1.28 million shares or 1.49 % in Mar 31 2025.


• More on KURA's Balance Sheets

 Market Capitalization (Millions) 526
 Shares Outstanding (Millions) 87
 Total Debt (Millions $) 10
 Revenue (TTM) (Millions $) 68
 Net Income (TTM) (Millions $) -182
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 89
   


  News about Kura Oncology Inc Earnings

Kura Oncology Inc's Rising Outlays in Q3 2023 Raise Investor Concerns



The recently published financial results of Kura Oncology Inc have raised concerns among investors regarding the company's performance during the July to September 30, 2023 reporting season. The disappointing operating deficit of $-42.473 million, coupled with a growing shortfall of $-38.602 million, indicates potential challenges that may impact the company's future prospects. Investors are eagerly awaiting the arrival of a new business model and pondering how these results will shape the company's path going forward.
Operating Deficit and Stakeholders' Expectations:
During the July to September 30, 2023 reporting period, Kura Oncology Inc incurred an operating deficit of $-42.473 million....

Kura Oncology Inc Reports Loss in Q2 2023, But Stock Performance Shows Promise

Financial News Report: Kura Oncology Inc Announces Operating Loss, but Shows Positive Stock Performance
In the Major Pharmaceutical Preparations industry, while the focus is generally on the big players, some lesser-known companies are also making headlines with their financial results. One such company, Kura Oncology Inc (KURA), recently reported an operating loss of $-40.003 million for the second quarter of 2023, which indicates a decline compared to the operating loss of $-35.333 million in the same quarter of the previous year.
Despite the widening operating loss, Kura Oncology's management has been taking proactive measures to secure steady revenue sources and improve the firm's financial perfo...

Restructuring at Kura Oncology Inc Leads to Significant Financial Challenges in First Quarter of 2023

Kura Oncology Inc (KURA) has been facing some serious financial setbacks, with a cumulative net loss of $-137 million recorded during the 12 months leading up to the first quarter of 2023. This has resulted in a negative return on investment of -32.26%, which is definitely a cause for concern for investors looking to profit from the healthcare sector. In fact, a total of 280 other companies in the same sector had a higher return on investment than KURA, which is a clear indication of the company's inability to perform up to the mark.
Furthermore, the company has not cited any top-line revenue figures for the January to March quarter of 2023. This has raised more doubts among the veterans of the Major Pha...


Date modified: 2025-05-04T12:08:21+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com